HPM Partners »

Inhibikase Therapeutics shares owned by HPM Partners

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by HPM Partners from 13F filings

Historical chart of HPM Partners investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by HPM Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by HPM Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $77k 38k 2.03

More positions owned by HPM Partners

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Ishares Tr Core S&p500 Etf (IVV)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Microsoft Corporation (MSFT)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Alphabet Cap Stk Cl A (GOOGL)
Alphabet Cap Stk Cl C (GOOG)
Amazon (AMZN)
Broadcom (AVGO)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Core Us Aggbd Et (AGG)
Procter & Gamble Company (PG)
Eli Lilly & Co. (LLY)

View all positions for HPM Partners

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Trails Edge Capital Partners
Fairmount Funds Management
BlackRock
ADAR1 Capital Management
Blackstone Group
Siren
Commodore Capital
Vanguard Capital Management
Millennium Management
Saturn V Capital Management
Kalehua Capital Management
Spruce Street Capital
Squadron Capital Management

View all funds holding Inhibikase Therapeutics